Skip to main content
Erschienen in: Tumor Biology 12/2015

01.12.2015 | Research Article

High expression of valosin-containing protein predicts poor prognosis in patients with breast carcinoma

Erschienen in: Tumor Biology | Ausgabe 12/2015

Einloggen, um Zugang zu erhalten

Abstract

Valosin-containing protein (VCP) is one of the AAA-ATPase superfamily members. The correlation between elevated expression of VCP and progression, prognosis, and the metastatic potential has been identified in various tumor types. However, the clinical impact of VCP in breast carcinoma has not been investigated. In the current study, the expression of VCP in 421 breast tumors and adjacent normal breast tissues was examined to investigate the correlation between VCP expression and clinicopathological features in patients with breast carcinoma. We found that the expression of VCP correlated with the TNM stage, Ki67 labeling, and lymph node metastasis (LNM). The expression of VCP was increased significantly in the cytoplasm of cancer cells compared to normal mammary epithelial cells, which was associated with decreased overall survival rates of patients with breast carcinoma (P < 0.001). In conclusion, this study demonstrates significant correlation between the cytoplasmic expression of VCP and adverse prognosis in breast carcinoma, suggesting that VCP may serve as a prognostic biomarker in breast carcinoma.
Literatur
1.
Zurück zum Zitat Cancer IAfRo. Latest world cancer statistics global cancer burden rises to 14.1 million new cases in 2012: marked increase in breast cancers must be addressed. World Health Organization 2013:1–3. Cancer IAfRo. Latest world cancer statistics global cancer burden rises to 14.1 million new cases in 2012: marked increase in breast cancers must be addressed. World Health Organization 2013:1–3.
2.
Zurück zum Zitat Xu Y, Hu B, Qin L, Zhao L, Wang Q, Wang Q, et al. Src-1 and twist1 expression positively correlates with a poor prognosis in human breast cancer. Int J Biol Sci. 2014;10:396–403.CrossRefPubMedPubMedCentral Xu Y, Hu B, Qin L, Zhao L, Wang Q, Wang Q, et al. Src-1 and twist1 expression positively correlates with a poor prognosis in human breast cancer. Int J Biol Sci. 2014;10:396–403.CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Meyer H, Bug M, Bremer S. Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system. Nat Cell Biol. 2012;14:117–23.CrossRefPubMed Meyer H, Bug M, Bremer S. Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system. Nat Cell Biol. 2012;14:117–23.CrossRefPubMed
4.
Zurück zum Zitat Min T, Bodas M, Mazur S, Vij N. Critical role of proteostasis-imbalance in pathogenesis of COPD and severe emphysema. J Mol Med (Berl). 2011;89:577–93.CrossRef Min T, Bodas M, Mazur S, Vij N. Critical role of proteostasis-imbalance in pathogenesis of COPD and severe emphysema. J Mol Med (Berl). 2011;89:577–93.CrossRef
5.
Zurück zum Zitat Ishigaki S, Hishikawa N, Niwa J-I, Iemura S-I, Natsume T, Hori S, et al. Physical and functional interaction between dorfin and valosin-containing protein that are colocalized in ubiquitylated inclusions in neurodegenerative disorders. J Biol Chem. 2004;279:51376–85.CrossRefPubMed Ishigaki S, Hishikawa N, Niwa J-I, Iemura S-I, Natsume T, Hori S, et al. Physical and functional interaction between dorfin and valosin-containing protein that are colocalized in ubiquitylated inclusions in neurodegenerative disorders. J Biol Chem. 2004;279:51376–85.CrossRefPubMed
7.
Zurück zum Zitat Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801–6.CrossRefPubMedPubMedCentral Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801–6.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Yamamoto S, Tomita Y, Hoshida Y, Iizuka N, Kidogami S, Miyata H, et al. Expression level of valosin-containing protein (p97) is associated with prognosis of esophageal carcinoma. Clin Cancer Res. 2004;10:5558–65.CrossRefPubMed Yamamoto S, Tomita Y, Hoshida Y, Iizuka N, Kidogami S, Miyata H, et al. Expression level of valosin-containing protein (p97) is associated with prognosis of esophageal carcinoma. Clin Cancer Res. 2004;10:5558–65.CrossRefPubMed
9.
Zurück zum Zitat Yamamoto S, Tomita Y, Hoshida Y, Sakon M, Kameyama M, Imaoka S, et al. Expression of valosin-containing protein in colorectal carcinomas as a predictor for disease recurrence and prognosis. Clin Cancer Res. 2004;10:651–7.CrossRefPubMed Yamamoto S, Tomita Y, Hoshida Y, Sakon M, Kameyama M, Imaoka S, et al. Expression of valosin-containing protein in colorectal carcinomas as a predictor for disease recurrence and prognosis. Clin Cancer Res. 2004;10:651–7.CrossRefPubMed
10.
Zurück zum Zitat Yi P, Higa A, Taouji S, Bexiga MG, Marza E, Arma D, et al. Sorafenib-mediated targeting of the AAA(+) ATPase p97/VCP leads to disruption of the secretory pathway, endoplasmic reticulum stress, and hepatocellular cancer cell death. Mol Cancer Ther. 2012;11:2610–20.CrossRefPubMed Yi P, Higa A, Taouji S, Bexiga MG, Marza E, Arma D, et al. Sorafenib-mediated targeting of the AAA(+) ATPase p97/VCP leads to disruption of the secretory pathway, endoplasmic reticulum stress, and hepatocellular cancer cell death. Mol Cancer Ther. 2012;11:2610–20.CrossRefPubMed
11.
Zurück zum Zitat Tsujimoto Y, Tomita Y, Hoshida Y, Kono T, Oka T, Yamamoto S, et al. Elevated expression of valosin-containing protein (p97) is associated with poor prognosis of prostate cancer. Clin Cancer Res. 2004;10:3007–12.CrossRefPubMed Tsujimoto Y, Tomita Y, Hoshida Y, Kono T, Oka T, Yamamoto S, et al. Elevated expression of valosin-containing protein (p97) is associated with poor prognosis of prostate cancer. Clin Cancer Res. 2004;10:3007–12.CrossRefPubMed
12.
Zurück zum Zitat Dai RM, Chen E, Longo DL, Gorbea CM, Li CC. Involvement of valosin-containing protein, an atpase co-purified with ikappaBalpha and 26 s proteasome, in ubiquitin-proteasome-mediated degradation of ikappaBalpha. J Biol Chem. 1998;273:3562–73.CrossRefPubMed Dai RM, Chen E, Longo DL, Gorbea CM, Li CC. Involvement of valosin-containing protein, an atpase co-purified with ikappaBalpha and 26 s proteasome, in ubiquitin-proteasome-mediated degradation of ikappaBalpha. J Biol Chem. 1998;273:3562–73.CrossRefPubMed
13.
Zurück zum Zitat Dai RM, Li C-CH. Valosin-containing protein is a multi-ubiquitin chain-targeting factor required in ubiquitin–proteasome degradation. Nat Cell Biol. 2001;3:740–4.CrossRefPubMed Dai RM, Li C-CH. Valosin-containing protein is a multi-ubiquitin chain-targeting factor required in ubiquitin–proteasome degradation. Nat Cell Biol. 2001;3:740–4.CrossRefPubMed
14.
Zurück zum Zitat Karin M, Yamamoto Y, Wang QM. The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Discov. 2004;3:17–26.CrossRefPubMed Karin M, Yamamoto Y, Wang QM. The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Discov. 2004;3:17–26.CrossRefPubMed
15.
Zurück zum Zitat Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 1996;274:782–4.CrossRefPubMed Beg AA, Baltimore D. An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 1996;274:782–4.CrossRefPubMed
16.
Zurück zum Zitat Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer-rationale and promise. Cancer Cell. 2003;4:257–62.CrossRefPubMed Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer-rationale and promise. Cancer Cell. 2003;4:257–62.CrossRefPubMed
17.
Zurück zum Zitat Klein JB, Barati MT, Wu R, Gozal D, Sachleben Jr LR, Kausar H, et al. Akt-mediated valosin-containing protein 97 phosphorylation regulates its association with ubiquitinated proteins. J Biol Chem. 2005;280:31870–81.CrossRefPubMed Klein JB, Barati MT, Wu R, Gozal D, Sachleben Jr LR, Kausar H, et al. Akt-mediated valosin-containing protein 97 phosphorylation regulates its association with ubiquitinated proteins. J Biol Chem. 2005;280:31870–81.CrossRefPubMed
18.
Zurück zum Zitat Matkovic B, Juretic A, Separovic V, Novosel I, Separovic R, Gamulin M, et al. Immunohistochemical analysis of ER, PR, HER-2, CK 5/6, p63 and EGFR antigen expression in medullary breast cancer. Tumori. 2008;94:838–44.PubMed Matkovic B, Juretic A, Separovic V, Novosel I, Separovic R, Gamulin M, et al. Immunohistochemical analysis of ER, PR, HER-2, CK 5/6, p63 and EGFR antigen expression in medullary breast cancer. Tumori. 2008;94:838–44.PubMed
19.
Zurück zum Zitat Hsu C-Y, Ho DM-T, Yang C-F, Lai C-R, Yu I-T, Chiang H. Interobserver reproducibility of Her-2/neu protein overexpression in invasive breast carcinoma using the DAKO HercepTest®. Am J Clin Pathol. 2002;118:693–8.CrossRefPubMed Hsu C-Y, Ho DM-T, Yang C-F, Lai C-R, Yu I-T, Chiang H. Interobserver reproducibility of Her-2/neu protein overexpression in invasive breast carcinoma using the DAKO HercepTest®. Am J Clin Pathol. 2002;118:693–8.CrossRefPubMed
20.
Zurück zum Zitat Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–50.CrossRefPubMedPubMedCentral Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–50.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Simon R, Mirlacher M, Sauter G. Tissue microarrays; molecular diagnosis of cancer, Springer, 2004, pp 377–89. Simon R, Mirlacher M, Sauter G. Tissue microarrays; molecular diagnosis of cancer, Springer, 2004, pp 377–89.
22.
Zurück zum Zitat Fessart D, Marza E, Taouji S, Delom F, Chevet E. P97/CDC-48: proteostasis control in tumor cell biology. Cancer Lett. 2013;337:26–34.CrossRefPubMed Fessart D, Marza E, Taouji S, Delom F, Chevet E. P97/CDC-48: proteostasis control in tumor cell biology. Cancer Lett. 2013;337:26–34.CrossRefPubMed
23.
Zurück zum Zitat Asai T, Tomita Y, Nakatsuka SI, Hoshida Y, Myoui A, Yoshikawa H, et al. VCP (p97) regulates NFkB signaling pathway, which is important for metastasis of osteosarcoma cell line. Cancer Sci. 2002;93:296–304. Asai T, Tomita Y, Nakatsuka SI, Hoshida Y, Myoui A, Yoshikawa H, et al. VCP (p97) regulates NFkB signaling pathway, which is important for metastasis of osteosarcoma cell line. Cancer Sci. 2002;93:296–304.
24.
Zurück zum Zitat Xu S, Peng G, Wang Y, Fang S, Karbowski M. The AAA-ATPase p97 is essential for outer mitochondrial membrane protein turnover. Mol Biol Cell. 2011;22:291–300.CrossRefPubMedPubMedCentral Xu S, Peng G, Wang Y, Fang S, Karbowski M. The AAA-ATPase p97 is essential for outer mitochondrial membrane protein turnover. Mol Biol Cell. 2011;22:291–300.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Rumpf S, Lee SB, Jan LY, Jan YN. Neuronal remodeling and apoptosis require VCP-dependent degradation of the apoptosis inhibitor DIAP1. Development. 2011;138:1153–60.CrossRefPubMedPubMedCentral Rumpf S, Lee SB, Jan LY, Jan YN. Neuronal remodeling and apoptosis require VCP-dependent degradation of the apoptosis inhibitor DIAP1. Development. 2011;138:1153–60.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, et al. NF-κB activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A. 2004;101:10137–42.CrossRefPubMedPubMedCentral Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, et al. NF-κB activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A. 2004;101:10137–42.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Li T, Lu H, Shen C, Lahiri S, Wason M, Mukherjee D, et al. Identification of epithelial stromal interaction 1 as a novel effector downstream of Krüppel-like factor 8 in breast cancer invasion and metastasis. Oncogene 2013. Li T, Lu H, Shen C, Lahiri S, Wason M, Mukherjee D, et al. Identification of epithelial stromal interaction 1 as a novel effector downstream of Krüppel-like factor 8 in breast cancer invasion and metastasis. Oncogene 2013.
29.
Zurück zum Zitat Vandermoere F, El Yazidi-Belkoura I, Slomianny C, Demont Y, Bidaux G, Adriaenssens E, et al. The valosin-containing protein (VCP) is a target of Akt signaling required for cell survival. J Biol Chem. 2006;281:14307–13.CrossRefPubMed Vandermoere F, El Yazidi-Belkoura I, Slomianny C, Demont Y, Bidaux G, Adriaenssens E, et al. The valosin-containing protein (VCP) is a target of Akt signaling required for cell survival. J Biol Chem. 2006;281:14307–13.CrossRefPubMed
30.
Zurück zum Zitat Bose S, Chandran S, Mirocha JM, Bose N. The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol. 2006;19:238–45.CrossRefPubMed Bose S, Chandran S, Mirocha JM, Bose N. The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol. 2006;19:238–45.CrossRefPubMed
31.
Zurück zum Zitat Meyer MF, Seuthe IM, Drebber U, Siefer O, Kreppel M, Klein MO, et al. Valosin-containing protein (VCP/p97)-expression correlates with prognosis of HPV-negative oropharyngeal squamous cell carcinoma (OSCC). PLoS One. 2014;9, e114170.CrossRefPubMedPubMedCentral Meyer MF, Seuthe IM, Drebber U, Siefer O, Kreppel M, Klein MO, et al. Valosin-containing protein (VCP/p97)-expression correlates with prognosis of HPV-negative oropharyngeal squamous cell carcinoma (OSCC). PLoS One. 2014;9, e114170.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Zhu WW, Kang L, Gao YP, Hei Y, Dong J, Liu Y, et al. Expression level of valosin containing protein is associated with prognosis of primary orbital MALT lymphoma. Asian Pac J Cancer Prev. 2013;14:6439–43.CrossRefPubMed Zhu WW, Kang L, Gao YP, Hei Y, Dong J, Liu Y, et al. Expression level of valosin containing protein is associated with prognosis of primary orbital MALT lymphoma. Asian Pac J Cancer Prev. 2013;14:6439–43.CrossRefPubMed
33.
Zurück zum Zitat Liu Y, Hei Y, Shu Q, Dong J, Gao Y, Fu H, et al. VCP/p97, down-regulated by microRNA-129-5p, could regulate the progression of hepatocellular carcinoma. PLoS One. 2012;7, e35800.CrossRefPubMedPubMedCentral Liu Y, Hei Y, Shu Q, Dong J, Gao Y, Fu H, et al. VCP/p97, down-regulated by microRNA-129-5p, could regulate the progression of hepatocellular carcinoma. PLoS One. 2012;7, e35800.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Valle CW, Min T, Bodas M, Mazur S, Begum S, Tang D, et al. Critical role of VCP/p97 in the pathogenesis and progression of non-small cell lung carcinoma. PLoS One. 2011;6, e29073.CrossRefPubMedPubMedCentral Valle CW, Min T, Bodas M, Mazur S, Begum S, Tang D, et al. Critical role of VCP/p97 in the pathogenesis and progression of non-small cell lung carcinoma. PLoS One. 2011;6, e29073.CrossRefPubMedPubMedCentral
Metadaten
Titel
High expression of valosin-containing protein predicts poor prognosis in patients with breast carcinoma
Publikationsdatum
01.12.2015
Erschienen in
Tumor Biology / Ausgabe 12/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3748-9

Weitere Artikel der Ausgabe 12/2015

Tumor Biology 12/2015 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.